Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
about
Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel DiseaseMaintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's DiseaseCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsThe bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in ratsEfficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management.Extraintestinal manifestations and complications in inflammatory bowel diseases.Basic and clinical aspects of osteoporosis in inflammatory bowel disease.The efficacy and safety of bisphosphonates for osteoporosis or osteopenia in Crohn's disease: a meta-analysis.Extraintestinal manifestations in inflammatory bowel disease.Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.High prevalence of osteoporotic vertebral fractures in patients with Crohn's diseaseMeasurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral densityCD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerinPrevention and treatment of osteoporosis in inflammatory bowel disease.Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females.Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis.Osteoporosis and inflammation.A review of osteoporosis management in younger premenopausal women.Association between fat mass, lean mass, and bone loss: the Dubbo Osteoporosis Epidemiology Study.Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.Bone Loss Prevention of Bisphosphonates in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Clinical relevance of changes in bone metabolism in inflammatory bowel disease.Manipulating bone disease in inflammatory bowel disease patients.Crohn's disease and risk of fracture: does thyroid disease play a role?Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.What is the role for bisphosphonates in IBD?Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation.Osteoporosis in inflammatory bowel disease.Metabolic Bone Disease in Gastrointestinal DisordersAll Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Con
P2860
Q22241416-9A30CC9C-56A5-4BFF-A0DB-A03B2875EDE7Q22242347-E17419FB-F66B-4310-B24E-9D0EB73A7E5CQ24614627-0198111C-EBF8-438E-84B6-53DDB7CD2BFFQ28569481-72753FE9-D50A-4465-8B06-DD6E189939D2Q30843177-D2CFE8E3-2B85-4247-B0E4-6E143C113D14Q33532262-12DC40CC-4289-4980-B675-589B39716BB3Q33866998-6C366B6C-3B93-4A0A-80F5-EF5E8C3592ADQ34225188-02DA2953-1918-492A-8887-C22048FDAA6FQ34487806-A9EE895D-A428-4B05-854E-0986209ECCE6Q34488386-00EFE60D-9EC1-4DC1-9C87-BEABF7DACCCBQ34497449-64FA1BD2-24C2-4372-A11F-6A8A0DA353EFQ35595126-91D3295E-8632-449C-A2F6-9D32D5350D44Q35596697-9AAD2869-091B-47A9-A9F7-C0B638239A46Q35597152-C9001BBA-1C7D-4910-AE3D-B66FB8AF19F5Q36569260-F7AEFE66-5DE7-41F2-9067-E37FDF8709C6Q37356514-FBB7F3FE-7A12-444C-AF2E-CD00A0E46C30Q37613371-060A880F-8A98-4EBE-ADDE-6F230BD792F1Q37756576-50551508-A999-44F3-9DDB-C3CDF4E9F593Q38170408-3A0EC3D6-233F-4E21-9ED1-F18573462885Q38429885-E12B3DCB-202C-4715-B031-778F121D93D6Q38904535-C7099B2B-08D9-4119-95D0-A56679C5CEF7Q40485920-BFA61607-2330-4743-9B7B-363285D1CE79Q41622305-C17212DD-A2EA-4005-8666-89736D4857C5Q42342936-6336B76F-7A63-4C28-AC9A-170173D37A96Q42406589-D2F011E4-21B3-4B3B-8B47-C8850684C849Q43201077-1029B9B3-7DAE-467F-AB81-C54B8AAFD555Q44778720-674E2BD5-5DD4-427B-9755-BA32147F83E2Q45368845-26C864BD-B66D-4558-AE05-396DD5E4AFFAQ46227890-6CDB3AFA-E799-4FCE-8637-C1E91BCA744AQ46888780-8DFDDC9A-13F2-4B46-A295-35D62784D6C1Q51187803-4F484E53-C467-4658-B7EF-6777F01B2EC0Q54960189-4B231C9A-76DC-4EDB-B040-F4D0CB72FAB5Q57169423-C3842EA6-08EF-4D73-A1EF-EB9E10935898Q57711910-9971A746-7BD8-4879-81BA-00CE34195B14
P2860
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@ast
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@en
type
label
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@ast
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@en
prefLabel
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@ast
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@en
P2093
P356
P1433
P1476
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
@en
P2093
Haderslev KV
Sorensen HA
Tjellesen L
P304
P356
10.1053/GAST.2000.16518
P407
P577
2000-09-01T00:00:00Z